Understanding ADHD Medication in the Workplace: Use Cases, Barriers, and the Role of Employers

November 19, 2025

‍

Last month, a senior analyst at a mid-sized tech company ran out of their ADHD medication. Not because they forgot to refill their prescription, but because their pharmacy had been out of stock for three weeks. Their manager's response? "You need to get it together."

This isn't an isolated incident. It's playing out across workplaces nationwide.

The Reality Behind the Headlines

You've probably heard someone say, "It seems like everyone has ADHD these days," or seen articles about college students using ADHD medication as a study drug. These narratives have consequences. They minimize the experiences of professionals who depend on medication not to get ahead, but to function at a baseline in the workplace.

The data tells a more nuanced story. Approximately 4-6% of adults in the United States are ADHD, though research suggests it remains significantly underdiagnosed. Meanwhile, stimulant medication shortages have become increasingly common. In 2022 and 2023, the FDA reported widespread shortages affecting millions of people with stimulant medication prescriptions.

Here's what gets lost in those conversations: ADHD brains process information differently. Stimulant medications don't work the same way in neurodivergent brains as they do in neurotypical ones. For someone with ADHD, these medications aren't performance enhancers; they're tools that help their brain process information in a way that aligns with how most workplaces operate.

Think of it this way: if your laptop's operating system were fundamentally different from everyone else's in the office, you'd need specific software to interface with company systems. That's closer to what ADHD medication does. It's not about curing ADHD or fundamentally changing who someone is. It's about accessing a tool that, for many people, enables them to live more fulfilling lives and contribute their talents effectively.

The Access Crisis No One's Talking About

Supply chain shortages for ADHD medications have become a recurring problem. When a neurotypical employee can't access their coffee machine, they might have a sluggish morning. When someone with ADHD can't access their medication for weeks at a time, they're suddenly managing their workload without the neurological support they've built their routines around.

The response from some managers reveals a fundamental misunderstanding. Telling someone to "get it together" when they're navigating a medication shortage ignores the reality of what these medications help with: organizing tasks, managing time, filtering distractions, and maintaining focus, to name a few. These are the exact capabilities needed to "get it together" in the first place.

And access issues extend beyond supply chains. High-masking neurodivergent individuals face additional barriers. Getting a diagnosis as an adult can be a lengthy, expensive process. Even with a diagnosis, finding a prescriber, navigating insurance requirements, and maintaining consistent access is a labyrinth many ADHD professionals are navigating.

Childhood vs Adulthood Criticisms

Stigma around ADHD medication looks very different in conversations surrounding children compared to adults.

In childhood, the stigma often centers on parents "overmedicalizing" their kids or "taking the easy way out" instead of addressing behavioral concerns through non-chemical means. In adulthood, it shifts to questions about whether someone "really needs it" or assumptions about seeking an unfair advantage.

Both miss the point. Not everyone with ADHD will choose medication, and that's fine. But for those who do, the decision typically comes after years of struggling with strategies that work for neurotypical brains but not for theirs. There's no shame in accessing what allows you to be your best.

What Employers Can Actually Do

If you're in a position to influence workplace policies, here are concrete steps that make a difference:

Build flexibility around daily schedules. Everyone has different preferences for getting their work done. Those who take ADHD medications often build in some time for the drugs to become effective in the morning and know that they will wear off by late afternoon or evening. If someone is able to structure their own day, a mid-day deep working session will likely be much more productive than an early morning or a late afternoon session. So it is beneficial for employers to consider personal workstyle and schedules when scheduling meetings and deliverables. Typically, this is easily accomplished by asking employees what time works for them for a 1:1 or follow-up meeting about XYZ topic, instead of just adding a time that works for management.

Show grace during shortage periods. When an employee discloses they're navigating a medication shortage, recognize this isn't a personal failing. It's a systemic issue affecting their ability to do precisely the things you'll be asking them to do.

Educate your management team. Most managers haven't received training on neurodiversity or what ADHD actually means in a professional context. A basic understanding that ADHD medication helps neurodivergent brains process information, that access can be inconsistent, and that this isn't about work ethic or capability can transform how these situations are handled.

Examine your benefits and support systems. Does your health insurance make ADHD diagnosis and treatment accessible? Do your policies accommodate the reality that ADHD medication often requires ongoing appointment schedules for prescription management? Are neurodivergent employees comfortable disclosing their needs without fear of being seen as less capable?

The Bottom Line

This isn't about advocating for one specific approach or claiming everyone with ADHD needs medication. It's about recognizing that for professionals who do use ADHD medication, access and support matter. These employees aren't asking for an unearned advantage, but rather for the tools that help them show up as their best selves.

The next time you hear someone suggest ADHD is overdiagnosed or that medication is about enhancement rather than necessity, remember the professional trying to prioritize fifteen urgent tasks while their brain screams that they're all equally important, waiting for a pharmacy to restock a medication they've been taking for years.

We can do better. Given the numerous talented neurodivergent professionals contributing at a high level to our workplaces, we should want to.

References

1. Kessler, R. C., et al. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163(4), 716-723.
2. Staley BS, Robinson LR, Claussen AH, et al. Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023. MMWR Morb Mortal Wkly Rep 2024;73:890–895. DOI: http://dx.doi.org/10.15585/mmwr.mm7340a1
3. U.S. Food and Drug Administration. (2022-2023). Drug Shortages Database: Amphetamine Mixed Salts. https://www.accessdata.fda.gov/scripts/drugshortages/
4. Hinshaw, S. P., et al. (2022). Adult ADHD, substance use, and criminality: A multi-decade longitudinal study. Journal of Clinical Child & Adolescent Psychology, 51(4), 678-693.
5. Quinn, P. O., & Madhoo, M. (2014). A review of attention-deficit/hyperactivity disorder in women and girls: Uncovering this hidden diagnosis. The Primary Care Companion for CNS Disorders, 16(3).
6. Morgan, P. L., et al. (2013). Racial and ethnic disparities in ADHD diagnosis from kindergarten to eighth grade. Pediatrics, 132(1), 85-93.
7. Mowlem, F. D., et al. (2019). Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. European Child & Adolescent Psychiatry, 28(4), 481-489.
8. Barkley, R. A. (2015). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (4th ed.). New York: Guilford Press.
9. Faraone, S. V., & Larsson, H. (2019). Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry, 24(4), 562-575.
10. Volkow, N. D., et al. (2009). Evaluating dopamine reward pathway in ADHD: Clinical implications. JAMA, 302(10), 1084-1091.
11. Able, S. L., et al. (2007). Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychological Medicine, 37(1), 97-107.
12. Antshel, K. M., et al. (2013). Advances in understanding and treating ADHD. BMC Medicine, 11(1), 72.
13. Barbaresi, W. J., et al. (2021). Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: A prospective study. The Lancet, 398(10295), 123-134.

‍